Literature DB >> 17063271

Screening for large rearrangements of the BRCA2 gene in Spanish families with breast/ovarian cancer.

Sara Gutiérrez-Enríquez1, Miguel de la Hoya, Cristina Martínez-Bouzas, Ana Sanchez de Abajo, Teresa Ramón y Cajal, Gemma Llort, Ignacio Blanco, Elena Beristain, Eduardo Díaz-Rubio, Carmen Alonso, María-Isabel Tejada, Trinidad Caldés, Orland Diez.   

Abstract

Germ-line mutations in BRCA1 and BRCA2 are responsible for about 30-60% of the hereditary breast and ovarian cancer (HBOC). A large number of point mutations have been described in both genes. However, large deletions and duplications that disrupt one or more exons are overlooked by point mutation detection approaches. Over the past years several rearrangements have been identified in BRCA1, while few studies have been designed to screen this type of mutations in BRCA2. Our aim was to estimate the prevalence of large genomic rearrangements in the BRCA2 gene in Spanish breast/ovarian cancer families. The multiplex ligation-dependent probe amplification (MLPA) was employed to search gross deletions or duplications of BRCA2 in 335 Spanish moderate to high-risk breast/ovarian cancer families previously screened negative for point mutations by conventional methods. Four different and novel large genomic alterations were consistently identified by MLPA in five families, respectively: deletions of exon 2, exons 10-12 and exons 15-16 and duplication of exon 20 (in two families). RT-PCR experiments confirmed the deletion of exons 15-16. All patients harbouring a genomic rearrangement were members of high-risk families, with three or more breast/ovarian cancer cases or the presence of breast cancer in males. We provide evidence that the BRCA2 rearrangements seem to account for a relatively small proportion of familial breast cancer cases in Spanish population. The screening for these alterations as part of the comprehensive genetic testing can be recommended, especially in multiple case breast/ovarian families and families with male breast cancer cases.

Entities:  

Mesh:

Year:  2006        PMID: 17063271     DOI: 10.1007/s10549-006-9376-8

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  16 in total

1.  Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.

Authors:  Xavier Gabaldó Barrios; Mª Desamparados Sarabia Meseguer; Miguel Marín Vera; Ana Isabel Sánchez Bermúdez; José Antonio Macías Cerrolaza; Pilar Sánchez Henarejos; Marta Zafra Poves; Mª Rosario García Hernández; Encarna Cuevas Tortosa; Ángeles Aliaga Baño; Verónica Castillo Guardiola; Pedro Martínez Hernández; Isabel Tovar Zapata; Enrique Martínez Barba; Francisco Ayala de la Peña; José Luis Alonso Romero; José Antonio Noguera Velasco; Francisco Ruiz Espejo
Journal:  Fam Cancer       Date:  2017-10       Impact factor: 2.375

2.  A multi-gene panel study in hereditary breast and ovarian cancer in Colombia.

Authors:  A M Cock-Rada; C A Ossa; H I Garcia; L R Gomez
Journal:  Fam Cancer       Date:  2018-01       Impact factor: 2.375

3.  BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.

Authors:  Inmaculada de Juan; Sarai Palanca; Asunción Domenech; Lidia Feliubadaló; Ángel Segura; Ana Osorio; Isabel Chirivella; Miguel de la Hoya; Ana Beatriz Sánchez; Mar Infante; Isabel Tena; Orland Díez; Zaida Garcia-Casado; Ana Vega; Àlex Teulé; Alicia Barroso; Pedro Pérez; Mercedes Durán; Estela Carrasco; M José Juan-Fita; Rosa Murria; Marta Llop; Eva Barragan; Ángel Izquierdo; Javier Benítez; Trinidad Caldés; Dolores Salas; Pascual Bolufer
Journal:  Fam Cancer       Date:  2015-12       Impact factor: 2.375

4.  A novel TP53 germline inframe deletion identified in a Spanish series of Li-fraumeni syndrome suspected families.

Authors:  Patricia Llovet; Francisco J Illana; Lorena Martín-Morales; Miguel de la Hoya; Pilar Garre; M Dolores Ibañez-Royo; Pedro Pérez-Segura; Trinidad Caldés; Vanesa García-Barberán
Journal:  Fam Cancer       Date:  2017-10       Impact factor: 2.375

5.  Analysis of BRCA1/BRCA2 genes' contribution to breast cancer susceptibility in high risk Jewish Ashkenazi women.

Authors:  Tal Distelman-Menachem; Tal Shapira; Yael Laitman; Bella Kaufman; Frida Barak; Sean Tavtigian; Eitan Friedman
Journal:  Fam Cancer       Date:  2008-09-17       Impact factor: 2.375

6.  Large BRCA1 and BRCA2 genomic rearrangements in Polish high-risk breast and ovarian cancer families.

Authors:  Helena Rudnicka; Tadeusz Debniak; Cezary Cybulski; Tomasz Huzarski; Jacek Gronwald; Jan Lubinski; Bohdan Gorski
Journal:  Mol Biol Rep       Date:  2013-09-25       Impact factor: 2.316

7.  The deletion of exons 3-5 of BRCA1 is the first founder rearrangement identified in breast and/or ovarian cancer Spanish families.

Authors:  Sarai Palanca; Inmaculada de Juan; Gema Perez-Simó; Eva Barragán; Isabel Chirivella; Eduardo Martínez; Oscar Fuster; Pascual Bolufer
Journal:  Fam Cancer       Date:  2013-03       Impact factor: 2.375

8.  Preimplantation genetic diagnosis using combined strategies on a breast cancer patient with a novel genomic deletion in BRCA2.

Authors:  Qingxue Wang; Judy F C Chow; William S B Yeung; Estella Y L Lau; Vivian C Y Lee; Ernest H Y Ng; Pak-Chung Ho
Journal:  J Assist Reprod Genet       Date:  2014-10-11       Impact factor: 3.412

9.  Inherited and acquired alterations in development of breast cancer.

Authors:  Piera Rizzolo; Valentina Silvestri; Mario Falchetti; Laura Ottini
Journal:  Appl Clin Genet       Date:  2011-11-14

10.  Frequency of Rearrangements Versus Small Indels Mutations in BRCA1 and BRCA2 Genes in Turkish Patients with High Risk Breast and Ovarian Cancer.

Authors:  Hülya Yazıcı; Seda Kılıç; Demet Akdeniz; Özge Şükrüoğlu; Şeref Buğra Tuncer; Mukaddes Avşar; Gözde Kuru; Betül Çelik; Seden Küçücük; Pınar Saip
Journal:  Eur J Breast Health       Date:  2018-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.